RYTM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RYTM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Rhythm Pharmaceuticals's work in process for the quarter that ended in Mar. 2024 was $2.54 Mil.
The historical data trend for Rhythm Pharmaceuticals's Inventories, Work In Process can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Pharmaceuticals Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
Inventories, Work In Process | Get a 7-Day Free Trial | - | - | - | - | 1.10 |
Rhythm Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Inventories, Work In Process | Get a 7-Day Free Trial | - | 2.95 | 3.50 | 1.10 | 2.54 |
That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.
Joseph Shulman | officer: Chief Technical Officer | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
Hunter C Smith | officer: CFO and Treasurer | C/O GENESEE & WYOMING INC., 20 WEST AVENUE, DARIEN CT 06820 |
Jennifer Chien | officer: EVP, Head of North America | C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 15203 |
Christopher Paul German | officer: Corporate Controller & CAO | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
Pamela J. Cramer | officer: Chief Human Resources Officer | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
William T. Roberts | officer: Chief Accounting Officer | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
Yann Mazabraud | officer: EVP, Head of International | C/O TREVI THERAPEUTICS, INC., 195 CHURCH STREET, FLOOR 14, NEW HAVEN CT 06510 |
Linda Shapiro Manning | officer: Chief Medical Officer | C/O RHYTHM PHARMACEUTICALS, 222 BERKELEY STREET, SUITE 1200, BOSTON MA 02116 |
David P Meeker | director | C/O PENWEST PHARMACEUTICALS CO, 39 OLD RIDGEBURY ROAD SUITE 11, DANBURY CT 06810 |
Todd Foley | director, 10 percent owner | THE JOHN HANCOCK TOWER, 200 CLARENDON STREET 54TH FLOOR, BOSTON MA 02116 |
Lynn A. Tetrault | director | 12701 COMMONWEALTH DRIVE, SUITE 9, FORT MYERS FL 33913 |
Camille L Bedrosian | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Ra Capital Healthcare Fund Lp | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Nithya Desikan | officer: Chief Commercial Officer | 82 BAY STATE ROAD, BELMONT MA 02478 |
Rajeev M. Shah | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
From GuruFocus
By Marketwired • 10-10-2023
By Marketwired • 07-17-2023
By sperokesalga sperokesalga • 06-06-2023
By Marketwired • 09-08-2023
By Marketwired • 08-28-2023
By GuruFocus Research • 11-07-2023
By sperokesalga sperokesalga • 04-18-2023
By sperokesalga sperokesalga • 05-22-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.